Bredesen in Mediterranean practice.

A different starting question.

The Bredesen protocol did not begin with a drug. It began with a question most Alzheimer's research had not asked seriously enough: what if cognitive decline is not one disease with one cause, but a final common symptom of several distinct upstream processes running in parallel? Dr Dale Bredesen, working out of UCLA and the Buck Institute for Research on Aging, built a clinical framework around that question — one that manages dementia not as a single diagnosis to be managed, but as a syndrome with identifiable, individually manageable drivers.

The Bredesen protocol — sometimes referenced clinically as ReCODE — is a precision-medicine approach to cognitive decline. It replaces the single-drug, single-target model with a multi-domain diagnostic workup, followed by a personalised intervention plan addressing whichever of the contributing processes are active in a given patient. This is the framework Clinic82 draws on when a patient presents with mild cognitive impairment, early Alzheimer's risk, or a strong family history and genuine concern.

It is worth being direct about where the evidence stands. The published Bredesen literature — several case series and cohort papers by Bredesen and colleagues — reports improvement in cognitive testing across addressed patients, but the studies to date are largely uncontrolled, and no randomised controlled trial has yet established that the protocol prevents or reverses Alzheimer's disease at a population level. We use the Bredesen framework because its diagnostic logic is sound and its interventions are individually evidence-based; we do not present it to patients as a cure, and we say so.

Six drivers, one syndrome.

The Bredesen framework's central claim is that what gets labelled "Alzheimer's disease" is, in most patients, the downstream result of several distinct pathological processes, each of which can be measured and each of which can be independently addressed. The categories the Bredesen literature identifies are:

• Chronic inflammation — systemic or neuroinflammatory signalling that damages neuronal tissue over years.
• Brain atrophy — structural volume loss, particularly in the hippocampus, often measurable years before symptoms are clinically obvious.
• Cardiovascular issues — impaired cerebral perfusion, small-vessel disease, and the shared risk architecture between vascular disease and dementia.
• Nutrient deficiencies — B-vitamins, vitamin D, omega-3 status, and other deficiencies with direct neurocognitive relevance.
• Toxin exposure — heavy metals, mycotoxins, and other burdens that the Bredesen literature associates with a specific cognitive-decline subtype.
• Hormonal imbalance — thyroid, sex hormone, and insulin-signalling disruption, all of which have documented effects on cognitive function.

This is the piece of the Bredesen protocol we think is genuinely durable, independent of how the evidence for any single intervention within it eventually matures: cognitive decline is multi-factorial, and a diagnostic plan that only screens for amyloid or only screens for vascular risk will miss drivers that are, in many patients, both present and manageable.

The same framework, a different baseline.

The Bredesen protocol was developed and initially validated in a US clinical population, and its dietary and lifestyle recommendations were built around a US baseline — a population where the shift toward a lower-inflammatory, nutrient-dense diet represents a significant departure from typical intake. Our patient population in Limassol, and the broader Mediterranean and Gulf-adjacent population we see, starts somewhere different.

Three differences matter clinically. First, dietary baseline: a patient who has eaten a heritage Mediterranean diet — olive oil, oily fish, legumes, minimal processed sugar — for decades is not the same nutritional starting point as a patient being asked to adopt the Bredesen-recommended ketoflex 12/3 pattern from a standard Western diet. The intervention has to be calibrated to what is actually being changed, not assumed. Second, hormonal patterns: sun exposure, activity patterns, and regional dietary iodine intake all shift the baseline thyroid and vitamin D physiology we are working from, which changes how we interpret the hormonal-imbalance domain of the Bredesen panel. Third, cardiovascular risk profile: Mediterranean and Gulf-region cardiovascular epidemiology differs from the US pattern the original protocol assumes, both in typical lipid patterns and in prevalence of insulin resistance.

None of this invalidates the Bredesen framework. It means the framework's diagnostic logic transfers cleanly, while several of its specific numeric targets and intervention defaults need re-calibration for the patient actually in front of us.

The architecture stays.

Three elements of the Bredesen protocol we import without modification, because they are methodology rather than population-specific defaults:

• The multi-domain diagnostic panel — cognitive testing, volumetric MRI, inflammatory, metabolic, hormonal and nutrient panels, and genetic risk stratification where indicated. This is the backbone of the Bredesen approach and we run it in full.
• The personalised intervention plan — managing only the drivers that are actually active in this patient, rather than a fixed protocol applied uniformly. This is the feature that distinguishes Bredesen's approach from a generic "brain health" programme, and it is non-negotiable.
• Longitudinal monitoring — repeat cognitive testing and repeat biomarker panels at defined intervals, so the intervention plan is revised against evidence rather than run on a fixed schedule regardless of response.

Calibrated to the patient in front of us.

Three adjustments we make routinely when applying the Bredesen protocol in a Mediterranean clinical setting:

• Dietary emphasis — rather than transitioning a patient onto the ketoflex pattern from a US-standard diet, we build from the heritage Mediterranean diet already in place, tightening specific elements (refined carbohydrate load, omega-6:omega-3 ratio, meal timing for the intermittent-fasting component) rather than replacing the dietary foundation wholesale. Patients already eating well by Mediterranean standards need refinement, not reinvention.
• Climate-specific supplementation — year-round sun exposure in Cyprus does not guarantee adequate vitamin D status, and we do not assume it does; we measure it directly. But the supplementation targets and the seasonal variation we plan for differ meaningfully from a Bredesen protocol written for higher-latitude patients with genuine seasonal deficiency swings.
• Cerebrolysin as adjunct where indicated — for patients with confirmed vascular or neurodegenerative components on imaging, we add Cerebrolysin, a neuropeptide preparation with trial data in vascular cognitive impairment and post-stroke recovery, as an adjunct within the broader Bredesen-framework plan rather than as a substitute for the multi-domain workup. It is one lever inside the plan, not the plan itself.

Fit matters.

The Bredesen protocol, as we run it, is appropriate for patients with mild cognitive impairment, early-stage Alzheimer's disease, a strong family history of dementia with genuine concern, and mid-life executives presenting with cognitive complaints — word-finding difficulty, executive function slippage, subjective memory concern — that warrant investigation rather than reassurance alone.

It is not appropriate, and we say so directly rather than accepting every referral, for patients recovering from acute stroke in the immediate post-event period, patients with severe or late-stage dementia where the multi-domain intervention model has limited evidence of benefit, and patients who cannot realistically comply with a multi-domain plan spanning diet, sleep, exercise, and supplementation. The Bredesen protocol asks a great deal of a patient's daily routine. Where that commitment is not realistic, we say so before starting rather than after the fact.

The honest retrospective.

Two adjustments we are still refining in how we apply the Bredesen protocol to this patient population:

• Earlier volumetric MRI baselining. In several early cases we sequenced cognitive testing before imaging, on cost and scheduling grounds. Structural data earlier in the workup would have sharpened the initial driver map rather than requiring a second look once the picture was already partly built.
• More conservative claims in early patient communication. The Bredesen literature's case-series framing can read, to an anxious patient, as more definitive than the evidence supports. We now front-load the limitations of the evidence base explicitly at intake, rather than only when a patient asks directly.

Neither of these changes the framework itself. Both change how carefully and how early we apply it.